|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Petawatt and exawatt class lasers worldwide显示文摘In the 2015 review paper‘Petawatt Class Lasers Worldwide’a comprehensive overview of the current status of highpower facilities of>200 TW was presented.This was largely based on facility specifications,with some description of their uses,for instance in fundamental ultra-high-intensity interactions,secondary source generation,and inertial confinement fusion(ICF).With the 2018 Nobel Prize in Physics being awarded to Professors Donna Strickland and Gerard Mourou for the development of the technique of chirped pulse amplification(CPA),which made these lasers possible,we celebrate by providing a comprehensive update of the current status of ultra-high-power lasers and demonstrate how the technology has developed.We are now in the era of multi-petawatt facilities coming online,with 100 PW lasers being proposed and even under construction.In addition to this there is a pull towards development of industrial and multi-disciplinary applications,which demands much higher repetition rates,delivering high-average powers with higher efficiencies and the use of alternative wavelengths:mid-IR facilities.So apart from a comprehensive update of the current global status,we want to look at what technologies are to be deployed to get to these new regimes,and some of the critical issues facing their development. | Colin N.Danson Constantin Haefner Jake Bromage Thomas Butcher Jean-Christophe FChanteloup Enam A.Chowdhury Almantas Galvanauskas Leonida A.Gizzi Joachim Hein David I.Hillier Nicholas W.Hopps Yoshiaki Kato Efim A.Khazanov Ryosuke Kodama Georg Korn Ruxin Li Yutong Li Jens Limpert Jingui Ma Chang Hee Nam David Neely Dimitrios Papadopoulos Rory R.Penman Liejia Qian Jorge J.Rocca andrey A.Shaykin Craig W.Siders Christopher Spindloe Sándor Szatmári Raoul M.G.M.Trines Jianqiang Zhu Ping Zhu Jonathan D.Zuegel | 2019 | High Power Laser Science and Engineering2019，7，3： | 33 |
| 2 | Cirrhotic portal hypertension: From pathophysiology to novel therapeutics显示文摘Portal hypertension and bleeding from gastroesophageal varices is the major cause of morbidity and mortality in patients with cirrhosis. Portal hypertension is initiated by increased intrahepatic vascular resistance and a hyperdynamic circulatory state. The latter is characterized by a high cardiac output, increased total blood volume and splanchnic vasodilatation, resulting in increased mesenteric blood flow. Pharmacological manipulation of cirrhotic portal hypertension targets both the splanchnic and hepatic vascular beds. Drugs such as angiotensin converting enzyme inhibitors and angiotensin Ⅱ type receptor 1 blockers, which target the components of the classical renin angiotensin system(RAS), are expected to reduce intrahepatic vascular tone by reducing extracellular matrix deposition and vasoactivity of contractile cells and thereby improve portal hypertension. However, these drugs have been shown to produce significant offtarget effects such as systemic hypotension and renal failure. Therefore, the current pharmacological mainstay in clinical practice to prevent variceal bleeding and improving patient survival by reducing portal pressure is non-selective-blockers(NSBBs). These NSBBs work by reducing cardiac output and splanchnic vasodilatation but most patients do not achieve an optimal therapeutic response and a significant proportion of patients are unable to tolerate these drugs.Although statins, used alone or in combination with NSBBs, have been shown to improve portal pressure and overall mortality in cirrhotic patients, further randomized clinical trials are warranted involving larger patient populations with clear clinical end points. On the other hand, recent findings from studies that have investigated the potential use of the blockers of the components of the alternate RAS provided compelling evidence that could lead to the development of drugs targeting the splanchnic vascular bed to inhibit splanchnic vasodilatation in portal hypertension. This review outlines the mechanisms related to the pathogenesis of portal hypertension and attempts to provide an update on currently available therapeutic approaches in the management of portal hypertension with special emphasis on how the alternate RAS could be manipulated in our search for development of safe, specific and effective novel therapies to treat portal hypertension in cirrhosis. | Lakmie S Gunarathne Harinda Rajapaksha Nicholas Shackel Peter W Angus Chandana B Herath | 2020 | World Journal of Gastroenterology2020，26，40： | 24 |
| 3 | China Patient-centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction: Study Design显示文摘 | Rachel P Dreyer Xi Li Xue Du Nicholas S Downing Li Li Hai-Bo Zhang Fang Feng Wen-Chi Guan Xiao Xu Shu-Xia Li Zhen-Qiu Lin Frederick A Masoudi John A Spertus Harlan M Krumholz Li-Xin Jiang | 2016 | Chinese Medical Journal2016，，1： | 13 |
| 4 | An epigenomic approach to therapy for tamoxifen-resistant breast cancer显示文摘Tamoxifen 是为雌激素受体 alpha 的前线治疗(ERα) 在绝经前的女人的积极的胸肿瘤。然而,到 tamoxifen 的抵抗发生在许多病人。嗯仍然与获得的 tamoxifen 抵抗在乳癌房间的生长起一个关键作用,建议那 ERα为治疗仍然是一个有效目标 tamoxifen 抵抗(Tam-R ) 乳癌。以识别 ERα 的新奇管理者;发信号,通过对 histone 甲基修饰词的一幅小规模的 siRNA 屏幕,我们发现了 WHSC1, histone H3K36 methyltransferase, ERα 的一个积极管理者;在乳癌房间发信号。我们证明 WHSC1 被招募到 ERα由 BET 蛋白质 BRD3/4 的基因,并且便于 ERα基因表示。小分子的赌注蛋白质禁止者 JQ1 potently 压制了经典 ERα发信号的小径和在文化的 Tam-R 乳癌房间的生长。用一个 Tam-R 乳癌异种皮移植老鼠模型,我们与 JQ1 和 ER degrader fulvestrant 由 JQ1 和联合治疗的强壮的长持续的效果在 vivo 反胸癌症活动示威了。一起拿,我们提供 epigenomic 蛋白质 BRD3/4 和 WHSC1 是雌激素受体发信号的必要管理者并且是为 Tam-R 乳癌的治疗的新奇治疗学的目标的证据。 | Qin Feng Zheng Zhang Martin J Shea Chad J Creighton Cristian Coarfa Susan G Hilsenbeck Rainer Lanz Bin He Lei Wang Xiaoyong Fu Agostina Nardone Yongcheng Song James Bradner Nicholas Mitsiades Constantine S Mitsiades C Kent Osborne Rachel Schiff Bert W O'Malley | 2014 | Cell Research2014，24，7： | 10 |
| 5 | Elucidation of the ‘Honeycrisp’ pedigree through haplotype analysis with a multi-family integrated SNP linkage map and a large apple (Malus×domestica) pedigree-connected SNP data set显示文摘The apple(Malus×domestica)cultivar Honeycrisp has become important economically and as a breeding parent.An earlier study with SSR markers indicated the original recorded pedigree of‘Honeycrisp’was incorrect and‘Keepsake’was identified as one putative parent,the other being unknown.The objective of this study was to verify‘Keepsake’as a parent and identify and genetically describe the unknown parent and its grandparents.A multi-family based dense and high-quality integrated SNP map was created using the apple 8 K Illumina Infinium SNP array.This map was used alongside a large pedigree-connected data set from the RosBREED project to build extended SNP haplotypes and to identify pedigree relationships.‘Keepsake’was verified as one parent of‘Honeycrisp’and‘Duchess of Oldenburg’and‘Golden Delicious’were identified as grandparents through the unknown parent.Following this finding,siblings of‘Honeycrisp’were identified using the SNP data.Breeding records from several of these siblings suggested that the previously unreported parent is a University of Minnesota selection,MN1627.This selection is no longer available,but now is genetically described through imputed SNP haplotypes.We also present the mosaic grandparental composition of‘Honeycrisp’for each of its 17 chromosome pairs.This new pedigree and genetic information will be useful in future pedigree-based genetic studies to connect‘Honeycrisp’with other cultivars used widely in apple breeding programs.The created SNP linkage map will benefit future research using the data from the Illumina apple 8 and 20 K and Affymetrix 480 K SNP arrays. | Nicholas P Howard Eric van de Weg David S Bedford Cameron P Peace Stijn Vanderzande Matthew D Clark Soon Li Teh Lichun Cai James J Luby | 2017 | Horticulture Research2017，4，1： | 9 |
| 6 | Systematic review of safety and efficacy of therapeutic endoscopic-retrograde-cholangiopancreatography during pregnancy including studies of radiation-free therapeutic endoscopic-retrograde-cholangiopancreatography显示文摘AIM To systematically review safety/efficacy of therapeutic endoscopic-retrograde-cholangiopancreatography(ERCP) performed during pregnancy, considering fetal viability, fetal teratogenicity, premature delivery, and future postpartum development of the infant.METHODS Systematic computerized literature search performed using PubMed with the key words 'ERCP' and 'pregnancy'. Two clinicians independently reviewed the literature, and decided on which articles to incorporate in this review based on consensus and preassigned priorities. Large clinical trials, meta-analyses, systematic reviews, and controlled trials were assigned higher priority than review articles or small clinical series, and individual case reports were assigned lowest priority. Dr. Cappell has formal training and considerable experience in conducting systematic reviews, with 4 published systematic reviews in peer-reviewed journals indexed in PubM ed during the last 2 years, and with a PhD in neurophysiology that involved 5 years of training and research in biomedical statistics.RESULTS Advances in imaging modalities, including abdominal ultrasound, MRCP, and endoscopic ultrasound, have generally obviated the need for diagnostic ERCP in nonpregnant and pregnant patients. Clinical experience with performing ERCP during pregnancy is burgeoning, with > 500 cases of therapeutic ERCP reported in the literature, aside from a national registry study of 58 patients. These studies show that therapeutic ERCP has a very high rate of technical success in clearing the bile duct of gallstones, and has a relatively low and acceptable rate of maternal and fetal complications. The great majority of births after therapeutic ERCP are full-term, have normal birth weights, and are healthy. A recent trend is performing ERCP without radiation to eliminate radiation teratogenicity. Systematic literature review reveals 147 cases of ERCP without fluoroscopy in 8 clinical series. These studies demonstrate extremely high technical success in endoscopically removing choledocholithiasis, favorable maternal outcomes with rare maternal ERCP complications, and excellent fetal outcomes. ERCP without fluoroscopy generally confirms proper biliary cannulation by aspiration of yellow bile per sphincterotome or leakage of yellow bile around an inserted guide-wire.CONCLUSION This systematic literature review reveals ERCP is relatively safe and efficacious during pregnancy, with relatively favorable maternal and fetal outcomes after ERCP. Recommendations are provided about ERCP indications, special ERCP techniques during pregnancy, and prospects for future research. | Mitchell S Cappell Stavros Nicholas Stavropoulos David Friedel | 2018 | World Journal of Gastrointestinal Endoscopy2018，10，10： | 8 |
| 7 | Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013显示文摘 | Marie Ng Tom Fleming Margaret Robinson Blake Thomson Nicholas Graetz Christopher Margono Erin C Mullany Stan Biryukov Cristiana Abbafati Semaw Ferede Abera Jerry P Abraham Niveen M E Abu-Rmeileh Tom Achoki Fadia S AlBuhairan Zewdie A Alemu Rafael Alfonso | 2014 | The Lancet2014，，： | 7 |
| 8 | Admission Glucose and In-hospital Mortality after Acute Myocardial Infarction in Patients with or without Diabetes: A Cross-sectional Study显示文摘 | Shi Zhao Karthik Murugiah Na Li Xi Li Zi-Hui Xu Jing Li Chen Cheng Hong Mao Nicholas S Downing Harlan M Krumholz Li-Xin Jiang | 2017 | Chinese Medical Journal2017，，7： | 6 |
| 9 | Ionotropic receptors and ion channels in ischemic neuronal death and dysfunction显示文摘到神经原的精力供应的损失在击期间导致被称为缺氧的去极的膜潜力的快速的损失。因为离子的流动的 dysregulation 和 ATP 的损失,缺氧的去极在神经原上导致巨大的生理的应力驾驶维持电气化学的坡度的离子泵。在这评论,我们在场一些被认为贡献神经原并且随后的缺氧的去极的 ionotropic 受体和离子隧道的概述,到房间死亡。为作为门 ligand 的阳离子隧道工作的 glutamate 和 ATP 的 ionotropic 受体在神经原的死亡和机能障碍是批评的。有趣地,二这些受体(P2X7 和 NMDAR ) 被显示了联合离子隧道到 pannexin-1 (Panx1 ) 。我们也讨论短暂受体潜力(TRP ) 的重要角色响应局部缺血的隧道和酸察觉到的离子隧道(ASIC ) 。从我们缺氧的去极的当前的理解出现的中央挑战是需要阐明这些离子隧道到的机械学、时间的相互关系充分在击期间在神经原上欣赏他们的影响。 | Nicholas L WEILINGER Valentyna MASLIEIEVA Jennifer BIALECKI Sarup S SRIDHARAN Peter L TANG Roger J THOMPSON | 2013 | Acta Pharmacologica Sinica2013，34，1： | 5 |
| 10 | A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing显示文摘 | Pablo Landgraf Mirabela Rusu Robert Sheridan Alain Sewer Nicola Iovino Alexei Aravin Sébastien Pfeffer Amanda Rice Alice O. Kamphorst Markus Landthaler Carolina Lin Nicholas D. Socci Leandro Hermida Valerio Fulci Sabina Chiaretti Robin Foà Julia Schliwka | 2007 | Cell2007，，7： | 4 |
| 11 | Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)显示文摘 | Fiona McPhee Amy K. Sheaffer Jacques Friborg Dennis Hernandez Paul Falk Guangzhi Zhai Steven Levine Susan Chaniewski Fei Yu Diana Barry Chaoqun Chen Min S. Lee Kathy Mosure Li-Qiang Sun Michael Sinz Nicholas A. Meanwell Richard J. Colonno Jay Knipe Paul S | 2012 | Antimicrobial Agents and Chemotherapy2012，，10： | 2 |
| 12 | Pan-retinal ganglion cell markers in mice, rats, and rhesus macaques显示文摘Univocal identification of retinal ganglion cells(RGCs) is an essential prerequisite for studying their degeneration and neuroprotection. Before the advent of phenotypic markers, RGCs were normally identified using retrograde tracing of retinorecipient areas. This is an invasive technique, and its use is precluded in higher mammals such as monkeys. In the past decade, several RGC markers have been described. Here, we reviewed and analyzed the specificity of nine markers used to identify all or most RGCs, i.e., pan-RGC markers, in rats, mice, and macaques. The best markers in the three species in terms of specificity, proportion of RGCs labeled, and indicators of viability were BRN3A, expressed by vision-forming RGCs, and RBPMS, expressed by vision-and non-vision-forming RGCs. NEUN, often used to identify RGCs, was expressed by non-RGCs in the ganglion cell layer, and therefore was not RGC-specific. γ-SYN, TUJ1, and NF-L labeled the RGC axons, which impaired the detection of their somas in the central retina but would be good for studying RGC morphology. In rats, TUJ1 and NF-L were also expressed by non-RGCs. BM88, ERRβ,and PGP9.5 are rarely used as markers, but they identified most RGCs in the rats and macaques and ERRβ in mice. However, PGP9.5 was also expressed by non-RGCs in rats and macaques and BM88 and ERRβ were not suitable markers of viability. | Francisco M.Nadal-Nicolás Caridad Galindo-Romero Fernando Lucas-Ruiz Nicholas Marsh-Amstrong Wei Li Manuel Vidal-Sanz Marta Agudo-Barriuso | 2023 | Zoological Research2023，44，1： | 2 |
| 13 | Hybrid diffractive-refractive lenses and achromats显示文摘 | Thomas S Nicholas G | 1988 | Applied Optics1988，27，14： | 2 |
| 14 | Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study显示文摘 | Julia Granerod Helen E Ambrose Nicholas WS Davies Jonathan P Clewley Amanda L Walsh Dilys Morgan Richard Cunningham Mark Zuckerman Ken J Mutton Tom Solomon Katherine N Ward Michael PT Lunn Sarosh R Irani Angela Vincent David WG Brown Natasha S Crowcroft | 2010 | The Lancet Infectious Diseases2010，，12： | 2 |
| 15 | Mycoplasma infections in growing cattle 显示文摘 | NICHOLAS R A J BAKER S AYLING R D | 2000 | Cattle Practice2000，，8： | 1 |
| 16 | Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip显示文摘 | WEINSTEIN R S NICHOLAS R W MANOLAGAS S C | 2000 | J Clin Endocrinol Metab2000，85，8： | 1 |
| 17 | Acute applications of noninvasive positive pressure ventilation显示文摘 | Timothy L Henry K Nicholas S | 2003 | Chest2003，124，： | 1 |
| 18 | Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures 显示文摘 | Nicholas S Abend MD Heather M | 2009 | Pediatr Crit Care Med2009，10，4： | 1 |
| 19 | Density functional study of cluster models of zeolites 1 Structure and acidity of hydroxyl groups in disioxane analogs显示文摘 | STEVE M S NICHOLAS J B | 1993 | J Phys Chem1993，97，38： | 1 |
| 20 | Ediacaran-Cambrian Sirab Formation of the A1 Huqf region, Sultanate of Oman 显示文摘 | Nicholas C J Gold S E P | 2012 | Geo Arabia Journal of the Middle East Petroleum Geosciences2012，17，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员